BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August

Day

• 1
• 2
• 3
• 5
• 6
• 7
• 8
• 9
• 10
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 24
• 26
• 27
• 28
• 29
• 30

• Press Releases

  Innate Pharma Files Its 2025 Universal Registration Document (Document D’enregistrement Universel) and 2025 Form 20-f Annual Report

  April 2, 2026

   · 

  3 min read
• Press Releases

  Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)

  April 2, 2026

   · 

  3 min read
• Press Releases

  Roivant Announces Expansion of Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) and Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

  April 2, 2026

   · 

  8 min read
• Press Releases

  Immunovant Announces Phase 3 Study Results for Batoclimab in Thyroid Eye Disease (TED)

  April 2, 2026

   · 

  5 min read
• Press Releases

  Brain Canada and the Krembil Foundation Fund New Neurodegeneration and Immunology Research

  April 2, 2026

   · 

  3 min read
• Press Releases

  AvenCell Therapeutics Announces First Patient Dosed in Phase I QUADvance Study with AVC-203, a Novel Allogeneic CD19/CD20 Dual-Targeting CAR-T Investigational Therapy for the Treatment of Relapsed/Refractory B-Cell Malignancies

  April 2, 2026

   · 

  7 min read
• Press Releases

  AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability

  April 2, 2026

   · 

  19 min read
• Press Releases

  Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

  April 2, 2026

   · 

  10 min read
• Press Releases

  CanWell Pharma Announces FDA Clearance of the IND for CAN016, a Dual-Payload ADC Targeting HER2, for ADC Pre-Treated Solid Tumors

  April 2, 2026

   · 

  2 min read
• Press Releases

  Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration

  April 2, 2026

   · 

  5 min read